Business
Placing to raise £5m
MedPal AI plc has successfully raised approximately £5.0 million through a placing at 3.5 pence per share, a price representing a 40% premium to its April 2026 placing. These funds will be used to complete the acquisition of Solid State Technologies Ltd, a profitable eMAR software business, for up to £0.5 million, thereby establishing a closed-loop care-home medication platform. Additionally, up to £3.0 million will be invested in stock and patient acquisition for the UK launch of oral Wegovy® on July 6, 2026, with each active private patient forecast to generate £2,400 in annual recurring revenue. The remaining proceeds will bolster working capital to support record NHS dispensing volumes and continued growth across the company's integrated platform. The company is also issuing 10,942,857 new ordinary shares to settle existing contractual obligations. Disclaimer*
About this update from Medpal Ai Plc
3 July 2026 MedPal AI plc ("MedPal AI" or the "Company") Placing to raise £5.0 million Funding to complete the acquisition of Solid State Technologies Ltd and capture the UK launch of oral Wegovy® MedPal AI Plc (AIM: MPAL, FRA: Z1N), the UK digital health and AI company, is pleased to announce that it has conditionally raised gross proceeds of approximately £5.0 million (the "Fundraise") through the issue of 142,857,133 new ordinary shares of £0.0002 each (the "Fundraise Shares") at a price of 3.5 pence per share (the "Issue Price"). The Fundraise has been arranged by OAK Securities as sole broker to the Fundraise. The Issue Price of 3.5 pence represents a 12.5 per cent. discount to the closing mid-market price of 4p per share on 2 July 2026 and a 40 per cent. premium to the price at which the Company raised £3 million in April 2026, reflecting the substantial operational and commercial progress delivered since that time. In addition, the Company is issuing 10,942,857 new ordinary shares (the "Settlement Shares") in settlement of existing contractual obligations, as set out below. Highlights • Gross proceeds of approximately £5.0 million raised at 3.5 pence per share - a 40 per cent. premium to the April 2026 placing price of 2.5 pence • Proceeds fund the acquisition of Solid State Technologies Ltd ("Solid State Technologies"), a profitable electronic Medicines Administration Record ("eMAR") software business, completing MedPal's closed-loop care-home medication platform • Positions the Company to capture the UK launch of the oral GLP-1 weight-loss pill (oral Wegovy®), launching in the UK on 6 July 2026, through investment in stock and patient acquisition • Strengthens working capital to support record NHS dispensing volumes and continued growth across the Company's vertically integrated platform • Strongly supported by institutional and new investors Use of Proceeds The net proceeds of the Fundraise will be deployed against two highly strategic, time-sensitive and revenue-generating opportunities, alongside general working capital: • Intended acquisition and integration of Solid State Technologies Ltd ("SST") (c.£0.5m subject to formal completion): SST provides the electronic Medicines Administration Records ("eMAR") software layer that sits at the point of care in the care homes wit...